Vitalis Therapeutics Inc. — The budget for the VitaFlow (VTX-401) program: a $243,040,000 authorized ceiling, $201,200,000 released through Gate 4, $101,000,000 spent as at 15 October 2026. Cost pools reconcile to stage tranches in both directions; every figure ties to the program fact base.
1. Three Numbers, Not One
A stage-gate program has three distinct budget figures at any moment, and reporting one of them as “the budget” misleads in a predictable direction.
| Figure | Amount | What it means |
|---|---|---|
| Authorized ceiling | $243,040,000 | The maximum the program may ever spend. Set at charter, changeable only by the Board. Most of it is not spendable today. |
| Released to date | $201,200,000 | Tranches actually released through Gate 4. This is the program's real spending authority at 15 October 2026. |
| Spent to date | $101,000,000 | 50% of released authority. The only figure that has left the building. |
2. Cost Pools
The base program of $217,000,000 by cost pool. This is the estimate, not the authorization — see §4 for what has actually been released.
| Cost pool | Amount | Share of base |
|---|---|---|
| Nonclinical pharmacology & GLP toxicology | $8,500,000 | 3.9% |
| CMC — early development | $6,200,000 | 2.9% |
| IND-enabling package & submission | $3,800,000 | 1.8% |
| Phase 1 clinical | $8,500,000 | 3.9% |
| Phase 2 clinical | $38,000,000 | 17.5% |
| Phase 3 clinical | $109,100,000 | 50.3% |
| NDA preparation & review support | $12,400,000 | 5.7% |
| CMC scale-up & process validation | $9,200,000 | 4.2% |
| Regulatory affairs | $7,600,000 | 3.5% |
| Program management | $5,300,000 | 2.4% |
| External fees, advisors & other non-labor | $8,400,000 | 3.9% |
| Base program | $217,000,000 | 100.0% |
Phase 3 alone is $109,100,000, 50% of the base program. That concentration is the single most important fact about this budget and the reason Gate 4 carries the weight it does: nearly half the program's cost sits behind one authorization taken at one meeting.
Clinical pools combined — Phase 1, 2 and 3 — total $155,600,000, or 72%. Program management is $5,300,000, 2.4%. A reader assessing whether this program is over-governed should weigh those two figures against each other.
3. Pool by Stage — the Reconciliation
The pool view (§2) and the tranche view (§4) describe the same $217,000,000 from different directions. This matrix is where they meet: every row sums to its pool total and every column sums to its stage tranche. Without it a reader has two tables that each claim to total the base program and no way to tie one to the other.
| Cost pool | S1 | S2 | S3 | S4 | S5 | Pool total |
|---|---|---|---|---|---|---|
| Nonclinical pharmacology & GLP toxicology | $8,500,000 | — | — | — | — | $8,500,000 |
| CMC — early development | $5,200,000 | $1,000,000 | — | — | — | $6,200,000 |
| IND-enabling package & submission | — | $3,800,000 | — | — | — | $3,800,000 |
| Phase 1 clinical | — | $8,500,000 | — | — | — | $8,500,000 |
| Phase 2 clinical | — | — | $38,000,000 | — | — | $38,000,000 |
| Phase 3 clinical | — | — | — | $109,100,000 | — | $109,100,000 |
| NDA preparation & review support | — | — | — | — | $12,400,000 | $12,400,000 |
| CMC scale-up & process validation | — | — | — | $9,200,000 | — | $9,200,000 |
| Regulatory affairs | $800,000 | $1,400,000 | $1,200,000 | $2,800,000 | $1,400,000 | $7,600,000 |
| Program management | $900,000 | $1,000,000 | $1,000,000 | $1,600,000 | $800,000 | $5,300,000 |
| External fees, advisors & other non-labor | $2,000,000 | $500,000 | $1,600,000 | $3,100,000 | $1,200,000 | $8,400,000 |
| Tranche total | $17,400,000 | $16,200,000 | $41,800,000 | $125,800,000 | $15,800,000 | $217,000,000 |
- Most pools live in exactly one stage. Phase 1, Phase 2, Phase 3, NDA preparation and CMC scale-up each sit wholly inside a single tranche. That is what makes tranche discipline meaningful — declining to release a stage genuinely stops the work rather than stranding it half-funded.
- Three pools run across all five stages — regulatory affairs, program management and external fees. These are the standing costs of having a program at all, and they are what would continue burning during a HOLD outcome.
- CMC early development is the only pool split across a gate, straddling Stages 1 and 2. That split is the manufacturing work that had to continue across the IND-enabling boundary, and it is the kind of detail a pool-only view hides entirely.
4. Tranche Release
No stage is funded before the gate preceding it carries. Each tranche is released on the gate decision and is spendable only against that stage's scope.
| Tranche | Released at | Stage window | Amount | Status |
|---|---|---|---|---|
| Stage 1 — Nonclinical & CMC | Gate 0 · 01 Mar 2022 | Mar 2022 – Dec 2022 | $17,400,000 | released |
| Stage 2 — IND & Phase 1 | Gate 1 · 31 Dec 2022 | Jan 2023 – May 2024 | $16,200,000 | released |
| Stage 3 — Phase 2 | Gate 3 · 31 May 2024 | Jun 2024 – Jun 2026 | $41,800,000 | released |
| Stage 4 — Phase 3 & NDA | Gate 4 · 30 Jun 2026 | Jul 2026 – Sep 2028 | $125,800,000 | released |
| Stage 5 — Review & Launch | Gate 5 · 30 Sep 2028 | Oct 2028 – Jun 2029 | $15,800,000 | not yet released |
| Total | — | — | $217,000,000 | — |
Gate 2 released no tranche. It is a submission gate: the IND is filed within the Stage 2 authorization, and the agency's thirty-day review is a regulatory clock rather than a governance decision. Gate 6 likewise releases nothing — it authorizes launch against money already released at Gate 5.
5. Rate Basis & the Internal / External Split
Internal roster cost derives from the resource envelopes: headcount, hours, and a blended rate per function inclusive of salary, benefits and overhead recovery.
| Function | FTE | Hours | Cost | Blended rate |
|---|---|---|---|---|
| Clinical Operations | 24 | 51,900 | $9,861,000 | $190 |
| Technical Operations / CMC | 16 | 30,200 | $5,436,000 | $180 |
| Biostatistics & Data Management | 12 | 22,600 | $4,068,000 | $180 |
| Regulatory Affairs | 10 | 18,900 | $3,969,000 | $210 |
| Clinical Development | 12 | 17,900 | $3,580,000 | $200 |
| Pharmacovigilance & Drug Safety | 8 | 14,200 | $2,556,000 | $180 |
| Quality Assurance (GxP) | 7 | 12,800 | $2,304,000 | $180 |
| Nonclinical Safety & Pharmacology | 5 | 9,400 | $1,692,000 | $180 |
| Program Management Office | 4 | 7,200 | $1,296,000 | $180 |
| Market Access & Commercial | 4 | 5,000 | $850,000 | $170 |
| Development Committee (oversight only) | 7 | 1,320 | $396,000 | $300 |
| Total internal roster | 109 | 191,420 | $36,008,000 | $188 |
The management consequence is direct: most of this budget is controlled through contracts rather than through line management. A program that manages its own headcount well and its vendor commitments loosely has optimized the small number. That is why commitments are staged to tranches (§6) rather than awarded whole.
The Development Committee envelope of $396,000 across 1,320 hours carries the highest blended rate in the roster, which is expected — it is executive time. It represents 0.18% of the base program, which is the honest cost of the governance the rest of this suite describes.
6. Vendor Commitments
Contracted commitments, staged to tranches. These are carried within the cost pools at §2, not additional to them — a vendor commitment is how a pool is spent, not a separate cost.
| Vendor | Stage | Work package | Value | Status |
|---|---|---|---|---|
| Meridian Clinical Research (CRO) | Stage 3 | Phase 2 execution | $22,400,000 | authorized |
| Stage 4 | Phase 3 execution, both pivotals + CV sub-study | $68,500,000 | authorized | |
| Stage 5 | Close-out, clinical study reports | $3,100,000 | not yet authorized | |
| Meridian Clinical Research (CRO) total | $94,000,000 | |||
| Aldergate Biologics (CMO) | Stage 2 | Phase 1 clinical supply | $1,400,000 | authorized |
| Stage 3 | Phase 2 clinical supply | $2,600,000 | authorized | |
| Stage 4 | Registration batches, process validation, stability | $9,200,000 | authorized | |
| Aldergate Biologics (CMO) total | $13,200,000 | |||
| Kestrel Laboratories (central lab) | Stage 2 | Phase 1 bioanalytical | $900,000 | authorized |
| Stage 3 | Phase 2 central lab and bioanalytical | $3,200,000 | authorized | |
| Stage 4 | Phase 3 central lab, CV sub-study assays | $8,900,000 | authorized | |
| Kestrel Laboratories (central lab) total | $13,000,000 | |||
| All contracted commitments | $120,200,000 |
Staging the commitment keeps the gate decision genuinely open. The Stage 5 packages remain unauthorized at the status date for exactly that reason.
Figures are nominal and carry no inflation escalation. Multi-year clinical contracts with Meridian and Aldergate are fixed-price by work package with a stated rate card for change orders, which places escalation exposure on the vendor inside a package and on the program only where scope moves.
7. Contingency
The reserve is $26,040,000, 12% of base. It is held at program level and released by the Development Committee against a named risk or an approved change. Functional leads cannot draw on it, and it is not a stage-level buffer.
| Draw | Against | Amount |
|---|---|---|
| CR-02 cardiovascular outcomes sub-study | Approved change (D-06) | $7,200,000 |
| I-02 CMC method transfer recovery | Materialised issue | $1,850,000 |
| Total drawn | — | $9,050,000 |
| Reserve remaining | — | $16,990,000 |
35% of the reserve is consumed with the largest cost pool — Phase 3 — still running. That is a position worth watching rather than an alarm: the larger draw funds a deliberate scope addition made on agency expectation, not an estimation failure.
8. Spend, Variance & Forecast
Closed stages
| Stage | Tranche released | Actual | Variance | % |
|---|---|---|---|---|
| Stage 1 — Nonclinical & CMC | $17,400,000 | $17,100,000 | $-300,000 | -1.7% |
| Stage 2 — IND & Phase 1 | $16,200,000 | $16,600,000 | +$400,000 | +2.5% |
| Stage 3 — Phase 2 | $41,800,000 | $40,900,000 | $-900,000 | -2.2% |
| Closed stages 1–3 | $75,400,000 | $74,600,000 | $-800,000 | -1.1% |
Stages 1 to 3 closed 1.1% under their combined tranches. Stage 2 ran over on Phase 1 recruitment (I-01, recovered inside the stage); Stage 3 came in under on Phase 2 site costs. Neither variance is large enough to be informative alone — the point of showing them is that closed stages are closed and their numbers do not move.
Open stage
| Measure | Value |
|---|---|
| Stage 4 tranche | $125,800,000 |
| Stage 4 spend to date | $26,400,000 |
| Consumed | 21% |
| Stage 4 window | Jul 2026 – Sep 2028 |
| Calendar elapsed | 13% |
Estimate at completion
| Component | Amount |
|---|---|
| Base program | $217,000,000 |
| Contingency drawn to date | $9,050,000 |
| Estimate at completion | $226,050,000 |
| Authorized ceiling | $243,040,000 |
| Headroom against ceiling | $16,990,000 |
The forecast assumes no further contingency draw, which is an assumption rather than a plan. With Phase 3 running and $16,990,000 of reserve remaining, the realistic question is not whether more will be drawn but whether what remains is adequate for what is left — one pivotal read-out, one filing, and one pre-approval inspection.
9. Cash Phasing
Annual spend across the seven fiscal years the program spans.
| Year | Spend | Share | Cumulative | Note |
|---|---|---|---|---|
| 2022 | $17,400,000 | 8.0% | $17,400,000 | Part year — program starts March |
| 2023 | $11,400,000 | 5.3% | $28,800,000 | |
| 2024 | $16,500,000 | 7.6% | $45,300,000 | |
| 2025 | $20,100,000 | 9.3% | $65,400,000 | |
| 2026 | $38,000,000 | 17.5% | $103,400,000 | |
| 2027 | $55,900,000 | 25.8% | $159,300,000 | Peak — Phase 3 at full enrolment |
| 2028 | $47,200,000 | 21.8% | $206,500,000 | |
| 2029 | $10,500,000 | 4.8% | $217,000,000 | Part year — launch November |
| Total | $217,000,000 | 100.0% | — |
The profile peaks in 2027 at $55,900,000 — Phase 3 at full enrolment across both pivotal trials plus the cardiovascular sub-study. Roughly 48% of the entire program is spent in those two years alone. That shape is what makes development programs difficult to fund at mid-size scale, and it is why tranche release matters commercially as well as for governance.
10. Accounting Treatment
All development cost is expensed as incurred under US GAAP; none is capitalized. Capitalisation of development cost is not available until regulatory approval is probable, which for a 505(b)(1) new molecular entity is not the case before approval. The program therefore has no asset on the balance sheet and the entire $217,000,000 is a charge against earnings across the seven fiscal years at §6.
11. Financial Controls
- Tranche discipline. Spend against a stage is capped at that stage's released tranche. Exceeding it is not an accounting matter — it is a governance breach and escalates to the Committee under the Development Committee Charter.
- Contingency draws are approved individually, against a named risk or change, and are recorded in the Contingency Register with the item they fund. No draw is approved as a lump-sum top-up to a stage.
- Vendor commitments are staged to tranches (§6), authorized by release notice per work package rather than as a single award.
- Purchase authority is delegated by value, per the thresholds in the Development Committee Charter. Any commitment above the functional lead threshold requires the Program Director; above the Program Director threshold, the Committee.
- Closed stages are not reopened. A variance discovered after a stage closes is recorded against the stage in which it is discovered, not retrospectively against the closed one.
- No earned value baseline is published for Stage 5. Stage 5 scope is not baselined to the level EVM requires, and publishing indices computed on an unbaselined stage would be fabricated precision — stated in the Program Charter §20 as an explicit non-authorization.
12. Reconciliation
Every figure on this page derives from the program fact base, which asserts these identities when it loads. A figure that cannot be reproduced from them does not appear here.
| Identity | Check |
|---|---|
| Cost pools sum to base | $217,000,000 = $217,000,000 ok |
| Tranches sum to base | $217,000,000 = $217,000,000 ok |
| Matrix rows sum to pool totals | 11 of 11 pools reconcile ok |
| Matrix columns sum to tranches | 5 of 5 stages reconcile ok |
| Cash phasing sums to base | $217,000,000 = $217,000,000 ok |
| Closed-stage actuals sum to reported spend | $74,600,000 = $74,600,000 ok |
| Base plus contingency equals ceiling | $217,000,000 + $26,040,000 = $243,040,000 ok |